Galapagos’ JAK1 Inhibitor Is One To Contend With Just today, Galapagos announced a major partnership with Abbott to develop its JAK1 specific inhibitor for the treatment of rheumatoid arthritis. This Belgium based biotech snagged a lucrative deal with $150 million in upfront payments. Upon the completion of Phase II studies, Abbott has the option to […]